SAB Biotherapeutics, Inc. announces the appointment of David Zaccardelli, Pharm.D., as Chair of the Board and Rita Jain, M.D., as an Independent Director.
The company is developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases.
David Zaccardelli brings over 20 years of biopharmaceutical leadership experience, including successful company growth and product launches.
Rita Jain has more than two decades of leadership experience in biopharmaceutical development across multiple therapeutic areas.
The appointments are expected to enhance SAB BIO's strategic direction and clinical development efforts.
David Zaccardelli's Appointment
Dr. Zaccardelli to serve as Chair of the Board, bringing extensive experience in leading companies from clinical to commercial stage.
Rita Jain's Appointment
Dr. Jain joins as an Independent Director with expertise in autoimmune and inflammatory disease drug development.
SAB BIO's Growth Trajectory
The appointments signify validation of the company's strategic direction and reinforce confidence in its potential for near-term growth.
- The addition of David Zaccardelli and Rita Jain to the Board is expected to provide valuable expertise to advance SAB BIO's pipeline of disease-modifying therapies.
- Their collective experience in biopharmaceutical development and clinical strategy positions the company well for future advancements in treating autoimmune diseases like T1D.
SAB Biotherapeutics, Inc.'s recent board appointments signal a pivotal moment for the company's growth and development of potentially transformative therapies for autoimmune diseases. With the expertise of Dr. Zaccardelli and Dr. Jain, SAB BIO is poised to make significant strides in its mission to improve patient outcomes in areas like type 1 diabetes.